PMID- 36630210
OWN - NLM
STAT- MEDLINE
DCOM- 20230113
LR  - 20231018
IS  - 1473-6551 (Electronic)
IS  - 1350-7540 (Linking)
VI  - 36
IP  - 1
DP  - 2023 Feb 1
TI  - Optic neuritis: current challenges in diagnosis and management.
PG  - 10-18
LID - 10.1097/WCO.0000000000001128 [doi]
AB  - PURPOSE OF REVIEW: The primary aim of this review is to describe the clinical 
      course, salient imaging features, and relevant serological profiles of common 
      optic neuritis (ON) subtypes. Key diagnostic challenges and treatment options 
      will also be discussed. RECENT FINDINGS: ON is a broad term that describes an 
      inflammatory optic nerve injury arising from a variety of potential causes. ON 
      can occur sporadically, however there is particular concern for co-associated 
      central nervous system (CNS) inflammatory syndromes including multiple sclerosis 
      (MS), neuromyelitis optic spectrum disorders (NMOSD), and myelin oligodendrocyte 
      glycoprotein antibody associated disease (MOGAD). The ON subtypes that often 
      herald MS, NMOSD, and MOGAD differ with respect to serological antibody profile 
      and neuroimaging characteristics, yet there is significant overlap in their 
      clinical presentations. A discerning history and thorough examination are 
      critical to rendering the correct diagnosis. SUMMARY: Optic neuritis subtypes 
      vary with respect to their long-term prognosis and accordingly, require different 
      acute treatment strategies. Moreover, delays in identifying MOGAD, and certainly 
      NMOSD, can be highly detrimental because affected individuals are vulnerable to 
      permanent vision loss and neurologic disability from relapses.
CI  - Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Benard-Seguin, Etienne
AU  - Benard-Seguin E
AD  - Department of Surgery, Section of Ophthalmology.
FAU - Costello, Fiona
AU  - Costello F
AD  - Department of Surgery, Section of Ophthalmology.
AD  - Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, 
      Canada.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20221205
PL  - England
TA  - Curr Opin Neurol
JT  - Current opinion in neurology
JID - 9319162
RN  - 0 (Aquaporin 4)
RN  - 0 (Myelin-Oligodendrocyte Glycoprotein)
RN  - 0 (Autoantibodies)
SB  - IM
MH  - Humans
MH  - *Neuromyelitis Optica/complications/diagnosis/therapy
MH  - Aquaporin 4
MH  - Myelin-Oligodendrocyte Glycoprotein
MH  - Autoantibodies
MH  - *Optic Neuritis/diagnosis/therapy
MH  - *Multiple Sclerosis/diagnosis
MH  - Inflammation
EDAT- 2023/01/12 06:00
MHDA- 2023/01/14 06:00
CRDT- 2023/01/11 12:13
PHST- 2023/01/11 12:13 [entrez]
PHST- 2023/01/12 06:00 [pubmed]
PHST- 2023/01/14 06:00 [medline]
AID - 00019052-202302000-00003 [pii]
AID - 10.1097/WCO.0000000000001128 [doi]
PST - ppublish
SO  - Curr Opin Neurol. 2023 Feb 1;36(1):10-18. doi: 10.1097/WCO.0000000000001128. Epub 
      2022 Dec 5.